ClinicalTrials.gov
public full text
Public Domain
Interferon-Alpha for Diabetes Mellitus Type 1
This study will see if interferon-alpha given early in the disease can stop or slow the immune attack on insulin-producing cells. In addition, the study will examine the safety and efficacy of interferon-alpha (given by mouth) to protect beta cell function. Patients between 3 and 25 years of age with Type 1 Diabetes Mellitus less then six weeks may be eligible for this study. All study-related tests and medications at the NIH Clinical Center are provided at no cost.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Natural History of Autoimmune Diabetes and Its Complications#1280042
- Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes#889812
- An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes#801350
- Stem Cell Educator Therapy in Diabetes#966939
- Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity#873252
Record · ID 1228262
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive